GoConqr hat ein neues Design! Sag uns, wie es dir gefällt.

Kostenlos registrieren

Quiz

MD13 Routes of delivery: Nasal and Pulmonary

Mer Scott 12 Fragen

Quiz starten

Dieses Quiz enthält Fragetypen, die sich im gewohnten Player öffnen.

Fragen in diesem Quiz (12)

  1. 1Nasal route is a non invasive administration and provides direct access to the systemic circulation.
    1. ARichtig
    2. BFalsch
  2. 2The nasal cavity is [blank_start]120-140[blank_end] mm deep, and is divided into two by a cartilaginous wall called nasal septum. The nose has a surface area of ~ [blank_start]160[blank_end] cm2 and a total volume of ~[blank_start]16-19[blank_end] ml.
    1. A120-140
    2. B160
    3. C16-19
  3. 3The nasal epithelium has ciliated, non-ciliated, [blank_start]goblet[blank_end] cells, and basal cells on a [blank_start]basement[blank_end] membrane. There are [blank_start]villi[blank_end] on all cells to increase surface area and a mucous layer.
    1. Agoblet
    2. Bbasement
    3. Cvilli
  4. 4Advantages of nasal drug delivery:
    1. A [blank_start]non invasive[blank_end] route
    2. Hepatic first –pass metabolism is [blank_start]absent[blank_end]
    3. Rapid drug [blank_start]absorption[blank_end]
    4. Quick onset of [blank_start]action[blank_end]
    5. The bioavailability of larger drug molecules can be improved by means of [blank_start]absorption enhancer[blank_end] or other approach.
    6. Better nasal [blank_start]bioavailability[blank_end] for smaller drug molecules
    7. Drugs which can [blank_start]not be absorbed orally[blank_end] may be delivered to the systemic circulation through nasal drug delivery system
    8. Convenient route when compared with parenteral route for [blank_start]long term therapy[blank_end]
    1. Anon invasive
    2. Babsent
    3. Cabsorption
    4. Daction
    5. Eabsorption enhancer
    6. Fbioavailability
    7. Gnot be absorbed orally
    8. Hlong term therapy
  5. 5Challenges for nasal delivery:
    1. The absorption [blank_start]enhancers[blank_end] used to improve nasal drug delivery system may have histological [blank_start]toxicity[blank_end] which is not yet clearly established
    2. Absorption surface area is [blank_start]less[blank_end] when compared to GIT
    3. Once the drug administered [blank_start]can not be removed[blank_end]
    4. Nasal [blank_start]irritation[blank_end]
    5. There is a [blank_start]risk[blank_end] of local side effects and irreversible [blank_start]damage of the cilia[blank_end] on the nasal mucosa
    1. Atoxicity
    2. Benhancers
    3. Cless
    4. Dcan not be removed
    5. Eirritation
    6. Frisk
    7. Gdamage of the cilia
  6. 6The respiratory tract branches from the trachea into bronchi (primary, secondary, and tertiary), then bronchioles, [blank_start]terminal[blank_end] bronchioles, into [blank_start]respiratory[blank_end] bronchioles, alveolar [blank_start]ducts[blank_end], and then alveolar [blank_start]sacs[blank_end].
    Alveolar sacs have type 1 and type 2 pneumocytes. At the air interface they have a layer of [blank_start]alveolar fluid[blank_end] with a [blank_start]surfactant[blank_end] layer on top. They contain macrophages.
    1. Aterminal
    2. Brespiratory
    3. Cducts
    4. Dsacs
    5. Ealveolar fluid
    6. Fsurfactant
  7. 7Advantages of pulmonary drug delivery for local action:
    1. [blank_start]Direct delivery[blank_end] to the location of the disease
    2. [blank_start]Rapid action[blank_end]
    3. A [blank_start]similar or superior[blank_end] therapeutic effect at a [blank_start]fraction[blank_end] of the systemic dose. (For example, 100–200 µg of salbutamol by inhalation is therapeutically equivalent to 2–4 mg of salbutamol oral dose)
    4. Reduce systemic [blank_start]side effects[blank_end]
    5. Reduce [blank_start]cost[blank_end]
    1. ADirect delivery
    2. BRapid action
    3. Csimilar or superior
    4. Dfraction
    5. Eside effects
    6. Fcost
  8. 8Advantages of Systemic Drug Delivery via the Lungs:
    • Rapid [blank_start]action[blank_end]
    • Less [blank_start]degradation[blank_end] of drug
    • Large surface area of absorption ([blank_start]100m2[blank_end])
    • [blank_start]Avoids[blank_end] first pass metabolism
    • [blank_start]Some[blank_end] absorption of peptides and proteins
    1. Aaction
    2. Bdegradation
    3. C100m2
    4. DAvoids
    5. ESome
  9. 9Which of these is not a disadvantage of pulmonary delivery?
    1. AOnly suitable for low dose (potent) drugs
    2. BEasier to swallow a tablet/capsule than to inhale a dose
    3. CVariable bioavailability depending on how effectively the patient uses the pMDI
    4. DBioavailability often higher than subcutaneous (eg for insulin)
  10. 10Protective Mechanisms of the Lung:
    1. [blank_start]Mucociliary escalator[blank_end]: composed of a mucus lining layer which covers the surface of the trachea, bronchi and bronchioles, including the terminal bronchioles and which is moved upwards towards the pharynx by the ciliated epithelium where it is generally swallowed
    2. [blank_start]Cough response[blank_end]: in the upper airways
    3. [blank_start]Phagocytic cells[blank_end]: scavenge particulate material which penetrates to the alveolar region of the lung
    4. [blank_start]Dissolution[blank_end]: of material, and removal by blood or lymphatics
    5. [blank_start]The structure[blank_end] of the respiratory system: complex system of branching tubes of progressively decreasing size, turns and decreased air flow
    1. AMucociliary escalator
    2. BCough response
    3. CPhagocytic cells
    4. DDissolution
    5. EThe structure

Informationen

Beschreibung
PHCY211 (Medicines) Quiz am MD13 Routes of delivery: Nasal and Pulmonary, erstellt von Mer Scott am 19/05/2018.
Sprache
English
Aufrufe
6
Schlagwörter
phcy211medicines
Bewertung
Noch keine Bewertungen
Bewerte dieses Quiz
Bewerte dieses Quiz

Feedback

Worum geht es?

Wie gefällt dir das neue Design?

Dein Eindruck